We first verified that CD19 deletion halted the development of both CLL and B1-cells in TC-RKCD19KO mice in the spleen and the blood, while the B2-cell development was less affected, still comprising approximately 20% of peripheral blood cells (Fig. 3a, b). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.